The healthcare industry is seeking greater incentives to promote private investment, sustained incentives for research and development particularly in antibiotic research, while calling for actions to address escalating Active Pharmaceutical Ingredient cost, including incentives for domestic manufacturers and a reduction in GST in the upcoming Interim Budget 2024-25.

Visit Site